REGISTER
First Generic Icotinib Tablet Approved in China
On July 10, 2026, China’s National Medical Products Administration approved the first generic icotinib tablet, developed by Kunshan Rotam Reddy Pharmaceutical Co., Ltd. The originator, Conmana from Betta Pharmaceuticals, is a first-generation EGFR-TKI for EGFR-mutant NSCLC across second-line, first-line, and adjuvant settings. While the compound patent expired in 2023, related crystal-form protections may extend to 2029-2034.

On July 10, 2026, China’s National Medical Products Administration (NMPA) approved the marketing of the first generic icotinib tablet, developed by Kunshan Rotam Reddy Pharmaceutical Co., Ltd. According to information currently disclosed on the NMPA website, this is the only generic icotinib tablet to have received marketing approval to date.

The originator product, Conmana from Betta Pharmaceuticals Co., Ltd., is a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) and was the first domestically developed small-molecule targeted anticancer drug in China. Icotinib tablets were first approved in China in May 2011. The product is indicated for second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), first-line treatment of EGFR mutation-positive locally advanced or metastatic NSCLC, and adjuvant treatment after surgery in patients with EGFR mutation-positive stage II-IIIA NSCLC.

The compound patent for icotinib expired in 2023. However, certain crystal-form patents and other related intellectual property protections may remain in force until 2029-2034.

According to estimates from the MedJ PharmaBI IPM database, hospital-channel sales of icotinib tablets reached approximately RMB 981 million in 2025, while total sales across all channels were estimated at approximately RMB 1.25 billion.

0
0
Loading